BioInvent granted patents for cancer programme
Sweden-based pharmaceutical research company BioInvent International has been granted additional patent protection for its BI-505 immune oncology programme for myeloma.
BioInvent announced today, September 19, that it has been granted patents in Japan, China and Russia for its BI-505 immune oncology programme.
The programme is in phase two and is for the treatment of multiple myeloma. It already has patents in the US and Europe.
BioInvent’s patents cover the use of BI-505 in the treatment of patients previously treated for cancer that have either not responded or who have relapsed.
The programme has received Orphan Drug Designation for multiple myeloma by the US Federal Drug Administration and the European Medicines Agency.
Michael Oredsson, president and CEO of BioInvent, said: “We are pleased to have added three more patent approvals to our intellectual property portfolio for BI-505 covering the treatment of relapsed cancer in these important territories.
“BI-505 has the potential to provide a life line to multiple myeloma patients who are no longer responsive to standard of care and who have no other treatments options for this fatal disease,” he added.
Multiple Myeloma is a type of bone marrow cancer which affects the plasma blood cells in the bone marrow. It affects many places in the body, including the spine, skull and ribs.
BI-505 is a fully human antibody targeting ICAM-1, a protein on the surface of cancer cells. It switches off the resistant cell’s survival signalling and stimulates the recruitment of macrophages that kill the myeloma tumour cells.
